Gene Solutions

At Oral Presentation Session #ESMOAsiaCongress2024, we unveiled latest validation data on HRD Insight, a cost-effective and reliable test developed to improve ovarian cancer treatment in developing countries. Key Highlights: ✅ Over 50% of ovarian cancer patients in Vietnam are HRD-positive, potentially eligible for PARPi therapy. ✅ HRD Insight offers high sensitivity, specificity, and concordance with other established HRD tests. ✅ Designed for low-quality DNA samples and applicable across other cancer types. This innovation paves the way for more patients in resource-constrained settings to access life-changing treatments. 🌍 🔗 Learn more about the study and our work in advancing cancer care: https://lnkd.in/grQ8xDAi #ESMOAsia2024 #PersonalizedCancerCare #OvarianCancer #HRDInsight #GeneSolutions #InnovationInHealth

10 cancer care pioneers from Gene Solutions are showcasing latest research at #ESMOAsia2024. Our presentations cover key advancements in cancer early detection, minimal residual disease #MRD tracking to predict relapse risks, treatment assessment, comprehensive genomic profiling #CGP and fusion-derived neoantigens for effective cancer vaccines design. Together, we advance the future of personalized oncology! #ESMOAsia24 Let take a closer look at our presentation here: https://lnkd.in/gh8Wqxxf

Inspiration, collaboration, and progress—that’s what #ESMOAsia2024 was all about. This gathering with over 4,000 oncology experts from across Asia-Pacific and beyond, we had the opportunity to exchange ideas and share the insights on the latest advancements in AI-enabled ctDNA technology in Comprehensive Genomic Profiling and Molecular Residual Disease Detection #MRD & Multi-Cancer Early Detection #MCED test performed at CAP-Accredited Laboratories in Singapore and Vietnam. A heartfelt thank-you to honored professors and doctors who visited us and shared invaluable perspectives on clinical applications and upcoming study designs, especially for lung and colorectal cancer. Your perspectives fuel our shared commitment to improving patient outcomes. 🌟 Stay tuned for more updates on ESMO Asia posters and related news! https://lnkd.in/gfqqeWF9 #ESMOAsia2024 #GeneSolutions #OncologyInnovation #AI-driven #MultiDimensional #CancerCare #ctDNA #PrecisionOncology

Gene Solutions is proud to present 1 Oral and 9 Posters at the #ESMOAsiaCongress2024 in Singapore, Dec 6-8. Join us at #BoothC401 to explore the future of personalized oncology with: 📌 1 Oral Presentation: Discover breakthroughs in Homologous Recombination Deficiency (HRD) testing for ovarian cancer. 📌 9 Cutting-Edge Posters: Early cancer detection, minimal residual disease (MRD) detection, relapse risk and treatment assessment, comprehensive genomic profiling (CGP), and the latest findings in fusion-derived neoantigens for effective cancer vaccine design. Together, let’s push the boundaries of personalized oncology. #ESMOAsia2024 #GeneSolutions #PersonalizedOncology #InnovativeResearch #HRD #MCED #MRD 

LATEST STUDY IN GENETICS OF MISCARRIAGE AT ASIA-PACIFIC CONGRESS IN MATERNAL FETAL MEDICINE (APCMFM 2024) We are proud to announce that Dr. Nguyen Vu Khanh and Dr. Nguyen Son Tung from Gene Solutions attended and presented important findings in the genetics of miscarriage at the 17th APCMFM 2024. The study examined fetal or placental samples from miscarriages occurring under 24 weeks of gestation. Its purpose was to investigate the causes of early miscarriages by identifying abnormal copy number variations (CNVs) and single-gene mutations in miscarriage fetuses. To achieve this, the researchers utilized Next-Generation Sequencing (NGS) to analyze DNA libraries and detect genetic abnormalities, focusing on 4503 genes through Clinical Exome Sequencing (CES). In 636 pregnancy loss cases, the study identified 223 cases with genetic abnormalities (96% chromosomal abnormalities and 4% single-gene variants). Chromosomal abnormalities are common genetic factors causing miscarriage. Identifying new genetic variations through this research may provide valuable insights into the molecular mechanisms leading to fetal demise. It provides reference data for the diagnosis and prevention of miscarriage. Dr. Nguyen Vu Khanh shared “Exploring the genetics of miscarriage reveals that 35% of cases are caused by fetal genetic abnormalities, highlighting the importance of genetic diagnosis in understanding the reasons for pregnancy loss and helping families achieve healthier pregnancies in the future.” Thank you to everyone who joined us at the APCMFM Congress and met our team of expert doctors! #GeneSolutions #GeneticResearch #MaternalFetalHealth #APCMFM2024 #InnovativeHealthcare

Join us at #ESMOAsia2024 to explore how Gene Solutions is advancing cancer care with ctDNA technology and AI-driven analysis. Discover innovations shaping the future of cancer prevention, personalized treatment, and empowering better patient outcomes. From December 6-8, visit us at Booth C401 at the Suntec Singapore Convention & Exhibition Centre to connect with experts and see how we’re driving the future of cancer care. In this year's ESMO ASIA Congress program, our R&D team will present multiple posters and oral presentations on Multi-cancer Early Detection, Minimal Residual Disease, and Genomic Profiling. Details of the presentation calendar will be updated in upcoming posts. #ESMOAsia2024 #GeneSolutions #OncologyInnovation #AI-driven #MultiDimensional #CancerCare #ctDNA #PrecisionOncology #Posters #Speakers #Exhibition 

What a meaningful October 29th! In honor of Breast Cancer Awareness Month, Gene Solutions Indonesia and Garuda Sentra Medika hosted an impactful event on early cancer detection. Led by Dr. Andhika Rahman, SpPD-KHOM, participants explored the power of Multi-Cancer Early Detection #MCED and gained insight into SPOT-MAS, Indonesia’s pioneering multi-cancer test. The day was filled with hands-on activities and heartfelt discussions, empowering everyone to embrace early action for better health. Learn more about this impactful event at the link here: https://lnkd.in/ggMxiJGr #GeneSolutionsIndonesia #GarudaSentraMedika #BreastCancerAwareness #SPOTMAS #MultiCancerEarlyDetection #MCED

We’re absolutely thrilled to welcome Mr. Evan Greger, M.Sc., M.B.A., as a Strategic Advisor to our Board of Directors at Gene Solutions. With nearly 30 years of experience in biotechnology, Mr. Evan’s unwavering passion for transforming healthcare and improving patients’ lives will be a game-changer for us. His impressive journey in developing innovative therapies and leading global teams aligns with our mission to empower precision cancer care. Mr. Evan’s insights and leadership will be instrumental as we continue to push the boundaries of genomic testing and multi-dimensional artificial intelligence in oncology. We can’t wait to work together and embark on this next chapter with Mr. Evan as we grow and evolve. Learn more about Mr. Evan’s remarkable journey and what’s next for Gene Solutions here: https://lnkd.in/gDG6VW-X Welcome aboard, Mr. Evan Greger! 🙌 

Explore the insightful symposium about Minimal Residual Disease (MRD) applications and global clinical trials, showcasing rapid advancements in circulating tumor DNA (ctDNA)-based testing at the TSCO Annual Meeting 2024. During Symposium 3 - Gene Solutions at the Thai Society of Clinical Oncology (TSCO) Annual Meeting held at Dusit Thani Pattaya, Thailand, oncology expert Professor Nick Pavlakis from the University of Sydney and Dr. Tu Ngoc Ly Lan from the Medical Genetics Institute HCMC shared insights on ctDNA MRD applications in cancer care. 📰Read the full summary here: https://lnkd.in/gdBu98jp  

🌟 Announcement of Analytical Validation for SPOT-MAS on Five Cancers Lacking Standard Screening (LSS) 🌟 We previously developed a SPOT-MAS assay to capture ctDNA signatures from 05 common cancer types (breast, lung, liver, colorectal, and stomach) and successfully facilitated early-stage detection in both retrospective (1) and prospective validation (2) studies. The recent study published in Future Oncology, "Evaluation of a Multimodal ctDNA-Based Assay for Detection of Aggressive Cancers Lacking Standard Screening Tests", extends the analysis to the 05 lethal LSS (lacking standard-of-care screening) cancers: endometrial, esophageal, head and neck, ovarian and pancreatic (3). The study revealed numerous shared ctDNA signals across 05 common cancers and 05 LSS cancers, demonstrating that SPOT-MAS could detect new lethal cancers with 96.2% specificity and 74.8% overall sensitivity. ✨ This proof-of-concept study shows that SPOT-MAS, a non-invasive test trained on five common cancer types, could detect a number of LSS cancer cases, potentially complementing existing screening programs.   Read the detailed publication summary here: https://lnkd.in/gSW7u5RJ #GeneSolutions #CancerDetection #FutureOncology #SPOTMAS #CancerResearch #EarlyDetection   🔑 References: (1) Le Son Tran et al. Analytical and clinical validation of a circulating tumor DNA–based assay for multicancer early detection.. JCO 42, 10548-10548(2024).DOI:10.1200/JCO.2024.42.16_suppl.10548 (2) Nguyen, H., Luong, B. A., Tran, D., Nguyen, T., Ngo, Q. D., Le, L. G. H., Ho, Q. C., Nguyen, H. T., Nguyen, C. M., Tran, V. U., Pham, T. V. N., Le, M. T., Le, N. a. T., Le, T. K., Nguyen, T. L., Pham, H. T., Le, H. T., Duong, H. D. T., Hoang, A. V., . . . Tran, D. T. (2021). Ultra-Deep Sequencing of Plasma-Circulating DNA for the Detection of Tumor- Derived Mutations in Patients with Nonmetastatic Colorectal Cancer. Cancer Investigation, 40(4), 354–365. https://lnkd.in/gSFNvrwH (3) Van Thien Nguyen, C., Nguyen, T. H. H., Vo, D. H., Van, T. T. V., Nguyen, G. T. H., Tran, T. H., Nguyen, T. H., Huynh, L. a. K., Nguyen, T. D., Tran, N., Ha, T. M. T., Le, P. T. Q., Truong, X. L., Nguyen, H. L., Tran, U. V., Hoang, T. Q., Nguyen, V. B., Le, V. C., Nguyen, X. C., . . . Tran, L. S. (2024). Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests. Future Oncology, 1–11. https://lnkd.in/gCQufHae